Coeptis Therapeutics switches focus from biotech to cryptocurrency mining
February 28, 2026
Coeptis Therapeutics has recently undergone a significant corporate shift. A transformative merger agreement with Z Squared Inc. has shifted the company’s focus from biopharmaceuticals to technology infrastructure, marking a pivotal moment in the organization’s evolution. With this monumental change, Coeptis Therapeutics has taken a bold step towards embracing a new strategic direction.
The merger will bring about changes in ownership and market listing, with Z Squared Inc.’s current owners holding a substantial majority stake in the combined entity. Existing Coeptis shareholders will retain a 21% interest in the newly formed company. Additionally, the company has sought a listing on the Nasdaq under a fresh ticker symbol, pending final approval.
By pivoting away from biotechnology to embrace the digital asset landscape, Coeptis Therapeutics has significantly altered its investment risk profile. While continuing its original research pipelines separately, the company’s future valuation will primarily depend on cryptocurrency market dynamics and the operational effectiveness of its mining infrastructure.
The strategic shift encompasses a core emphasis on Dogecoin and Litecoin, where Z Squared will focus on managing thousands of ASIC miners dedicated to these networks. With a substantial digital infrastructure valuation of approximately $660 million, the company aims to position itself as the largest publicly-listed Dogecoin mining operation in the U.S., marking a strategic coup in the industry.
Entering the digital asset infrastructure sector marks a fundamental departure from Coeptis Therapeutics’ roots in biopharmaceutical research, introducing a new realm of market dynamics and operational considerations. The completion of this new venture is contingent upon meeting customary closing conditions, signaling a new chapter for the company moving forward.
In a bid to streamline operations, the original biopharma business unit will undergo a legal separation as part of the restructuring process. Shareholders as of January 2, 2026, will receive shares in this new autonomous company through a stock dividend. With a valuation of around $75 million, the biotechnology division will enable investors to maintain exposure to potential value creation within the cell therapy and oncology programs.
This strategic transformation has opened up new possibilities for Coeptis Therapeutics and its shareholders. While the journey ahead may be fraught with uncertainties and challenges, the company’s foray into the digital asset sector signals a significant shift in its core business focus. As the merger progresses and operations begin under the banner of Z Squared Inc., investors will be keenly watching the company’s performance in the cryptocurrency mining landscape.
